Huntingtin gene promoter CpG sites (HTT promoter CpG sites) (HTT promoter CpG sites)

The Huntingtin gene promoter CpG sites are regulatory DNA sequences located at the 5' end of the HTT gene that play a pivotal role in controlling its transcriptional activity. These sites are characterized by a high density of cytosine-guanine dinucleotides, which are susceptible to DNA methylation, a key epigenetic mechanism for gene silencing (De Souza et al., 2016, Human Molecular Genetics). In patients with Huntington's disease, the expansion of CAG repeats in the HTT gene results in the production of a neurotoxic mutant protein. Consequently, these CpG sites have become a focal point for therapeutic intervention, specifically through epigenetic editing techniques designed to induce hypermethylation and suppress the expression of the toxic gene (Zheng et al., 2021, Frontiers in Genome Editing). By targeting the promoter's CpG sites, researchers aim to achieve long-term, stable reduction of huntingtin protein levels. This approach represents a novel frontier in neurodegenerative disease therapy, moving beyond traditional small molecules to direct genomic regulation. However, the strategy faces significant hurdles, including the need for precise delivery to the central nervous system and the avoidance of off-target epigenetic modifications that could disrupt global gene expression patterns (Biagioli et al., 2015, Human Molecular Genetics).

Other names

HTT promoter methylation sitesHuntingtin promoter CpG islandsHTT 5' regulatory region CpG sitesHTT 5' UTR CpG sites

Transcriptional silencing of the HTT gene through the induction of DNA methylation at promoter CpG sites, which recruits co-repressor complexes and alters chromatin accessibility (Zheng et al., 2021, Frontiers in Genome Editing).